Three cases of severe adolescent asthma treated with mepolizumab: lung function trajectories
Three cases of severe adolescent asthma treated with mepolizumab: lung function trajectories
复制标题
DOI：
10.5415/apallergy.2020.10.e13
复制
发表时间：
2020-04-01
影响因子：
1.7
通讯作者：
Fujisawa, Takao
中科院分区：
文献类型：
--
作者：
Hoshi, Miyuki;Matsunaga, Mayumi;Fujisawa, Takao
mepolizumab治疗儿童哮喘的实际经验仍然有限。我们报告了3例用美泊利单抗治疗严重青少年哮喘的患者。两名患者，一名12岁的男孩和一名14岁的女孩，对美泊利珠单抗反应良好，并显示肺功能明显改善，从治疗前的下降趋势。第3例患者是一名16岁的男孩，其治疗从omalizumab转换为mepolizumab，没有令人满意的缓解。2例成功病例的嗜酸性粒细胞计数为440和371/μ L，并伴有多种过敏性疾病，包括食物过敏。对他们的临床益处包括消除急性发作和运动诱发的哮喘。有趣的是，男孩的食物引起的胃肠道症状消失后，开始美泊利单抗治疗。
Real-world experience with mepolizumab for pediatric asthma is still limited. We report 3 patients who were treated with mepolizumab for severe adolescent asthma. Two patients, a 12-year-old boy and a 14-year-old girl, responded well to mepolizumab and showed apparent improvement in lung function from a downward trend over time before treatment. The third patient, a 16-year-old boy, whose treatment was switched from omalizumab to mepolizumab, did not have satisfactory response. The 2 successful cases had eosinophil counts of 440 and 371/mu L and multiple comorbid allergic diseases including food allergies. The clinical benefit to them included elimination of both exacerbation and exercise-induced asthma. Interestingly, the boy's food-induced gastrointestinal symptoms disappeared following start of mepolizumab treatment.